140,000 cells and 50M synapses make 1 adult fly brain
WEB18 hours ago · 140,000 cells and 50M synapses make 1 adult fly brain. A collaboration led by the Flywire Consortium and comprising hundreds of scientists has completed a whole map of the adult fruit fly brain after several decades of collaborative work. Nine years on from securing $3.84 million for a phase I clinical trial to test the formulation, with ...
Roche launches breakthrough 12-target PCR test | BioWorld
WEB15 hours ago · Roche AG’s new test using its temperature-activated generation of signal technology is the next step in PCR evolution, Igor Kozlov, head of Reagent Research and Design at Roche Diagnostics Solutions, told BioWorld. The Cobas Respiratory flex test can detect up to 12 of the most common respiratory viruses using a single PCR test.
BioWorld: The Daily Biopharmaceutical and Medical Technology …
WEBRadiopharmaceutical company Telix Pharmaceuticals Ltd. is continuing its buying spree to shore up dominance in the radiopharmaceutical market with its latest acquisition of... More in BioWorld Asia. Daily news and analysis of the global biotechnology, pharmaceutical and medical technology industries.
Multiple players rev their Engenes in bladder cancer
WEB1 day ago · Engene Holdings Inc.’s recent disclosure of pivotal phase II data with nonviral gene therapy detalimogene voraplasmid (also known as detalimogene, and previously as EG-70) – along with a planned protocol refinement – added intrigue to the non-muscle invasive bladder cancer space, which continues to percolate.
Prime’s $3.61B Bristol Myers deal is year’s fourth largest
WEB2 days ago · In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. in a research collaboration and license agreement totaling $3.61 billion. The two companies plan to develop reagents for ex vivo T-cell therapies. While the programs and targets have yet to be disclosed, BMS is expanding its CAR T development, begun more than five years ago, with this deal.
China - BioWorld
WEBSep 27, 2024 · China biotechs rise to challenge Ozempic, Wegovy. Sep. 17, 2024. By Marian (YoonJee) Chu. No Comments. Chinese pharmaceutical and biotech companies are leading development of glucagon-like peptide-1 receptor agonists as Novo Nordisk A/S and Eli Lilly and Co. edge closer to launching blockbuster therapies in China.
Today's news in brief | BioWorld
WEB4 days ago · Today's news in brief. Sep. 30, 2024. Appointments and advancements for September 30, 2024. New hires and promotions in the med-tech industry, including: SS Innovations, Zeus. Financings for September 30, 2024. Med-tech firms raising money in public or private financings, including: Eyenovia, …
Coronavirus - BioWorld
WEBSep 12, 2024 · The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note that we have added three critical tables, which are continuously updated: Vaccines and therapeutics in development. Diagnostics with U.S. FDA emergency use authorization.
China - BioWorld
WEBSep 24, 2024 · China biotechs rise to challenge Ozempic, Wegovy. Sep. 17, 2024. By Marian (YoonJee) Chu. No Comments. Chinese pharmaceutical and biotech companies are leading development of glucagon-like peptide-1 receptor agonists as Novo Nordisk A/S and Eli Lilly and Co. edge closer to launching blockbuster therapies in China.
Today's news in brief | BioWorld
WEBSep 27, 2024 · BioWorld briefs for September 27, 2024. Nine years on from securing $3.84 million for a phase I clinical trial to test the formulation, with results showing it overcame side effects that had confounded... Strategics tend to invest in med-tech companies they are looking to acquire or could be acquired. Furthermore, companies like Medtronic plc ...